$MRNS
MARINUS PHARMACEUTICALS, INC.

2023 Q4 Form 10-Q Financial Statement

#000155837023017857 Filed on November 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $7.190M $7.338M
YoY Change 0.39% 213.59%
Cost Of Revenue $887.0K $460.0K
YoY Change 203.77% 858.33%
Gross Profit $6.303M $6.880M
YoY Change -8.25% 200.17%
Gross Profit Margin 87.66% 93.76%
Selling, General & Admin $15.36M $14.87M
YoY Change 4.78% 11.05%
% of Gross Profit 243.66% 216.1%
Research & Development $26.38M $23.66M
YoY Change 23.14% 24.52%
% of Gross Profit 418.56% 343.91%
Depreciation & Amortization $125.0K $150.0K
YoY Change 52.44% -5.06%
% of Gross Profit 1.98% 2.18%
Operating Expenses $41.74M $38.53M
YoY Change 15.68% 18.95%
Operating Profit -$35.44M -$31.65M
YoY Change 21.31% 5.14%
Interest Expense -$2.551M $4.242M
YoY Change 31.09% 61.05%
% of Operating Profit
Other Income/Expense, Net $219.0K $1.021M
YoY Change -130.54% -995.61%
Pretax Income -$41.77M -$32.97M
YoY Change 27.83% -143.94%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$41.77M -$32.97M
YoY Change 22.94% -144.99%
Net Earnings / Revenue -580.93% -449.33%
Basic Earnings Per Share -$0.61
Diluted Earnings Per Share -$0.74 -$0.61
COMMON SHARES
Basic Shares Outstanding 54.57M 50.61M
Diluted Shares Outstanding 53.92M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $150.3M $176.4M
YoY Change -37.52% 4.82%
Cash & Equivalents $120.6M $140.4M
Short-Term Investments $29.72M $35.92M
Other Short-Term Assets $8.746M $11.70M
YoY Change 61.9% 122.65%
Inventory $2.413M $2.736M
Prepaid Expenses
Receivables $3.799M $4.281M
Other Receivables $0.00 $0.00
Total Short-Term Assets $165.2M $195.0M
YoY Change -34.52% 10.19%
LONG-TERM ASSETS
Property, Plant & Equipment $3.843M $3.909M
YoY Change -9.28% -29.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.819M $1.857M
YoY Change -37.36% -19.78%
Total Long-Term Assets $5.662M $5.766M
YoY Change -20.7% -26.41%
TOTAL ASSETS
Total Short-Term Assets $165.2M $195.0M
Total Long-Term Assets $5.662M $5.766M
Total Assets $170.9M $200.8M
YoY Change -34.14% 8.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.003M $2.626M
YoY Change -10.27% 61.9%
Accrued Expenses $22.86M $18.33M
YoY Change 17.01% -5.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $11.55M $7.700M
YoY Change
Total Short-Term Liabilities $40.62M $30.56M
YoY Change 62.39% 45.15%
LONG-TERM LIABILITIES
Long-Term Debt $61.42M $64.80M
YoY Change -13.51% -8.45%
Other Long-Term Liabilities $52.10M $50.90M
YoY Change 9.72% 362.43%
Total Long-Term Liabilities $113.5M $115.7M
YoY Change -4.2% 41.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $40.62M $30.56M
Total Long-Term Liabilities $113.5M $115.7M
Total Liabilities $154.1M $146.3M
YoY Change 7.4% 42.23%
SHAREHOLDERS EQUITY
Retained Earnings -$571.9M -$530.2M
YoY Change 32.85% 33.82%
Common Stock $55.00K $55.00K
YoY Change 10.0% 48.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.77M $54.54M
YoY Change
Total Liabilities & Shareholders Equity $170.9M $200.8M
YoY Change -34.14% 8.64%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$41.77M -$32.97M
YoY Change 22.94% -144.99%
Depreciation, Depletion And Amortization $125.0K $150.0K
YoY Change 52.44% -5.06%
Cash From Operating Activities -$26.99M -$25.17M
YoY Change 23.17% -15.1%
INVESTING ACTIVITIES
Capital Expenditures $34.00K $90.00K
YoY Change -63.04% -107.14%
Acquisitions
YoY Change
Other Investing Activities $6.500M $12.00M
YoY Change 3701.17% -88.82%
Cash From Investing Activities $6.466M $11.92M
YoY Change 8084.81% -88.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 661.0K 25.91M
YoY Change -99.3% -4845.42%
NET CHANGE
Cash From Operating Activities -26.99M -25.17M
Cash From Investing Activities 6.466M 11.92M
Cash From Financing Activities 661.0K 25.91M
Net Change In Cash -19.87M 12.66M
YoY Change -127.48% -83.33%
FREE CASH FLOW
Cash From Operating Activities -$26.99M -$25.17M
Capital Expenditures $34.00K $90.00K
Free Cash Flow -$27.03M -$25.26M
YoY Change 22.81% -11.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001267813
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesNoncurrent
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2600000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36576
dei Entity Registrant Name
EntityRegistrantName
MARINUS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0198082
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Radnor Corporate Center, Suite 500
dei Entity Address Address Line2
EntityAddressAddressLine2
100 Matsonford Rd
dei Entity Address City Or Town
EntityAddressCityOrTown
Radnor
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19087
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
801-4670
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
MRNS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54573581
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
140437000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
240551000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
35919000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4281000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6348000
CY2023Q3 us-gaap Inventory Net
InventoryNet
2736000
CY2022Q4 us-gaap Inventory Net
InventoryNet
77000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11667000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5402000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
195040000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
252378000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3909000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4236000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1857000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2904000
CY2023Q3 us-gaap Assets
Assets
200806000
CY2022Q4 us-gaap Assets
Assets
259518000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2626000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4461000
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
7700000
CY2023Q3 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
1901000
CY2022Q4 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
1020000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18328000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19536000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30555000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25017000
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
64783000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
71018000
CY2023Q3 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
32855000
CY2022Q4 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
29857000
CY2023Q3 mrns Contract With Customer Contract Liability Net Of Contract Asset
ContractWithCustomerContractLiabilityNetOfContractAsset
17105000
CY2022Q4 mrns Contract With Customer Contract Liability Net Of Contract Asset
ContractWithCustomerContractLiabilityNetOfContractAsset
16285000
CY2023Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
971000
CY2022Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
1341000
CY2023Q3 us-gaap Liabilities
Liabilities
146269000
CY2022Q4 us-gaap Liabilities
Liabilities
143518000
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
4043000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54580797
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54573490
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49650074
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49642767
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
55000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
584710000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
542428000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7307
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7307
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-71000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-530157000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-430521000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
54537000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
116000000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
200806000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
259518000
CY2023Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1891000
CY2022Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1785000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
10753000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
5088000
CY2023Q3 us-gaap Revenues
Revenues
7338000
CY2022Q3 us-gaap Revenues
Revenues
2340000
us-gaap Revenues
Revenues
23799000
us-gaap Revenues
Revenues
18316000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23661000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19002000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73006000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58488000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14868000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13389000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
45794000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42187000
mrns Cost Of License Fees
CostOfLicenseFees
1169000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
38984000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
32439000
us-gaap Costs And Expenses
CostsAndExpenses
119847000
us-gaap Costs And Expenses
CostsAndExpenses
101892000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-31646000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-30099000
us-gaap Operating Income Loss
OperatingIncomeLoss
-96048000
us-gaap Operating Income Loss
OperatingIncomeLoss
-83576000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1895000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
514000
us-gaap Investment Income Interest
InvestmentIncomeInterest
6366000
us-gaap Investment Income Interest
InvestmentIncomeInterest
610000
CY2023Q3 us-gaap Interest Expense
InterestExpense
4242000
CY2022Q3 us-gaap Interest Expense
InterestExpense
2634000
us-gaap Interest Expense
InterestExpense
12597000
us-gaap Interest Expense
InterestExpense
6982000
CY2022Q3 mrns Gain Loss On Sale Of Priority Review Voucher Net
GainLossOnSaleOfPriorityReviewVoucherNet
107375000
mrns Gain Loss On Sale Of Priority Review Voucher Net
GainLossOnSaleOfPriorityReviewVoucherNet
107375000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1021000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-114000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1105000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1179000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32972000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
75042000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101174000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
16248000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1752000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1538000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1752000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-32972000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
73290000
us-gaap Net Income Loss
NetIncomeLoss
-99636000
us-gaap Net Income Loss
NetIncomeLoss
14496000
CY2022Q3 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
1656000
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
336000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32972000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
71634000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-99636000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14160000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53920109
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37202269
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52755114
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37084060
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53920109
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37910511
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52755114
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38393754
CY2023Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
43000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-71000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32929000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
73290000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-99707000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
14496000
us-gaap Profit Loss
ProfitLoss
-99636000
us-gaap Profit Loss
ProfitLoss
14496000
mrns Gain Loss On Sale Of Priority Review Voucher Net
GainLossOnSaleOfPriorityReviewVoucherNet
107375000
us-gaap Depreciation
Depreciation
426000
us-gaap Depreciation
Depreciation
336000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1659000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1133000
mrns Accretion Of Revenue Interest Financing Debt
AccretionOfRevenueInterestFinancingDebt
4421000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
995000
us-gaap Share Based Compensation
ShareBasedCompensation
11638000
us-gaap Share Based Compensation
ShareBasedCompensation
11091000
mrns Increase Decrease Amortization Of Net Contract Asset Liability
IncreaseDecreaseAmortizationOfNetContractAssetLiability
1259000
mrns Increase Decrease Amortization Of Net Contract Asset Liability
IncreaseDecreaseAmortizationOfNetContractAssetLiability
1000000
mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
146000
mrns Non Cash Operating Lease Expense Operating Activities
NonCashOperatingLeaseExpenseOperatingActivities
194000
mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
300000
mrns Interest Expense Income On Lease Liabilities
InterestExpenseIncomeOnLeaseLiabilities
252000
mrns Fixed Assets Written Off
FixedAssetsWrittenOff
61000
mrns Fixed Assets Written Off
FixedAssetsWrittenOff
169000
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1169000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-930000
mrns Increase Decrease In Contract With Customer Refund Liability
IncreaseDecreaseInContractWithCustomerRefundLiability
-22163000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-2079000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-11057000
mrns Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable
6290000
mrns Increase Decrease In Prepaid Expense And Other Assets Noncurrent Assets Inventory And Accounts Receivable
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsNoncurrentAssetsInventoryAndAccountsReceivable
2313000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-3559000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1052000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-91009000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-90972000
mrns Proceeds From Sale Of Priority Review Voucher
ProceedsFromSaleOfPriorityReviewVoucher
107375000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
9000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
17000000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
51995000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
85000
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
1682000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35071000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
105693000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
783000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1763000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
28838000
mrns Payments Of Revenue Interest Financing Debt
PaymentsOfRevenueInterestFinancingDebt
737000
mrns Proceeds From Equity Offerings Net
ProceedsFromEquityOfferingsNet
25920000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25966000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30601000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-100114000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45322000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
240551000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
122927000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140437000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
168249000
mrns Unrealized Gain Loss On Short Term Investments Cash Flow
UnrealizedGainLossOnShortTermInvestmentsCashFlow
-71000
mrns Financing Costs
FinancingCosts
97000
us-gaap Interest Paid Net
InterestPaidNet
6540000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
903000
mrns Property And Equipment In Deposits Placed In Service
PropertyAndEquipmentInDepositsPlacedInService
1665000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
53486000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3378000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1733000
CY2022Q1 mrns Stock Issued During Period Value Related To License Agreement
StockIssuedDuringPeriodValueRelatedToLicenseAgreement
1169000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-19361000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
40405000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3817000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-39433000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4803000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3895000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
73290000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
82004000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
116000000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3741000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
74000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34730000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
85085000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3891000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
485000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-188000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31934000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
57339000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4006000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
298000
CY2023Q3 us-gaap Share Price
SharePrice
7.17
CY2023Q3 mrns Stock Issuance Costs
StockIssuanceCosts
529000
CY2023Q3 mrns Stock Issued During Period Value Equity Distribution Agreement
StockIssuedDuringPeriodValueEquityDistributionAgreement
25823000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
43000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-32972000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
54537000
us-gaap Net Income Loss
NetIncomeLoss
-99600000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-530200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from such estimates.</p>
mrns Number Of Customers
NumberOfCustomers
3
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
mrns Trade Receivable Payment Term
TradeReceivablePaymentTerm
P30D
CY2023Q3 us-gaap Cash
Cash
1200000
CY2023Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
139300000
CY2022Q4 us-gaap Cash
Cash
10600000
CY2022Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
230000000.0
CY2023Q3 us-gaap Interest Receivable
InterestReceivable
200000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
35990000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
118000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
189000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
35919000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1410000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
571000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
755000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
77000
CY2023Q3 us-gaap Inventory Net
InventoryNet
2736000
CY2022Q4 us-gaap Inventory Net
InventoryNet
77000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7159000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7061000
CY2023Q3 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
5303000
CY2022Q4 mrns Clinical Trials And Drug Development Current
ClinicalTrialsAndDrugDevelopmentCurrent
5725000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
594000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1417000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2445000
CY2023Q3 mrns Third Party Commercial Expenses Current
ThirdPartyCommercialExpensesCurrent
3708000
CY2022Q4 mrns Third Party Commercial Expenses Current
ThirdPartyCommercialExpensesCurrent
1880000
CY2023Q3 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
704000
CY2022Q4 mrns Lease Liability Short Term
LeaseLiabilityShortTerm
637000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
860000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
371000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18328000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19536000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.001
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-32972000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
73290000
us-gaap Net Income Loss
NetIncomeLoss
-99636000
us-gaap Net Income Loss
NetIncomeLoss
14496000
CY2022Q3 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
1656000
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
336000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-32972000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
71634000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-99636000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
14160000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53920109
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37202269
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
52755114
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37084060
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
708242
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
1309694
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53920109
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37910511
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52755114
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38393754
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8453977
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4735841
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8453977
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4566687
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4006000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3895000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11638000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11091000
CY2022 mrns Maximum Percentage Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.0999
CY2022 mrns Maximum Percentage Increase Or Decrease Of Beneficial Ownership For Exercise Of Pre Funded Warrants
MaximumPercentageIncreaseOrDecreaseOfBeneficialOwnershipForExerciseOfPreFundedWarrants
0.1999
CY2023Q3 mrns Maximum Shares Available For Issuance Value Equity Distribution Agreement
MaximumSharesAvailableForIssuanceValueEquityDistributionAgreement
75000000
mrns Equity Distribution Agreement Commission Percentage Maximum
EquityDistributionAgreementCommissionPercentageMaximum
0.030
mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
3700000
mrns Proceeds From Equity Offerings Net
ProceedsFromEquityOfferingsNet
25900000
mrns Stock Issued During Period Shares Equity Distribution Agreement
StockIssuedDuringPeriodSharesEquityDistributionAgreement
0
CY2023Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P78M
CY2023Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P60M
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P24M
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1000000.0
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1300000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1500000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2000000.0
CY2022Q3 us-gaap Lease Cost
LeaseCost
100000
CY2023Q3 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
400000
us-gaap Lease Cost
LeaseCost
400000
CY2023Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.110
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2022 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
206000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
840000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
642000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1688000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
180000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1508000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
704000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
804000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1508000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000.0
CY2023Q3 mrns Debt Instrument Minimum Liquidity Covenant
DebtInstrumentMinimumLiquidityCovenant
15000000.0
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
75000000
CY2023Q3 mrns Contractual Term Loan Exit Fees
ContractualTermLoanExitFees
2003000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4520000
CY2023Q3 us-gaap Notes Payable
NotesPayable
72483000
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
7700000
CY2023Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
64783000
CY2023Q3 us-gaap Notes Payable
NotesPayable
72483000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
11250000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
15000000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
48750000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
75000000
mrns Revenue Interest Financing Agreement Estimated Effective Annual Interest Rate
RevenueInterestFinancingAgreementEstimatedEffectiveAnnualInterestRate
0.18
CY2022Q4 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
30877000
mrns Revenue Interest Financing Agreement Non Cash Interest Income Expense
RevenueInterestFinancingAgreementNonCashInterestIncomeExpense
4421000
mrns Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
194000
mrns Revenue Interest Financing Agreement Payments
RevenueInterestFinancingAgreementPayments
-736000
CY2023Q3 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
34756000
CY2023Q3 mrns Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
1901000
CY2023Q3 mrns Revenue Interest Financing Payable Net Of Deferred Offering Costs Noncurrent
RevenueInterestFinancingPayableNetOfDeferredOfferingCostsNoncurrent
32855000
CY2023Q3 mrns Revenue Interest Financing Agreements
RevenueInterestFinancingAgreements
34756000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
500000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0

Files In Submission

Name View Source Status
mrns-20230930_cal.xml Edgar Link unprocessable
0001558370-23-017857-index-headers.html Edgar Link pending
0001558370-23-017857-index.html Edgar Link pending
0001558370-23-017857.txt Edgar Link pending
0001558370-23-017857-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mrns-20230930.xsd Edgar Link pending
mrns-20230930x10q.htm Edgar Link pending
mrns-20230930x10q004.jpg Edgar Link pending
mrns-20230930x10q007.jpg Edgar Link pending
mrns-20230930x10q008.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mrns-20230930xex31d1.htm Edgar Link pending
mrns-20230930xex31d2.htm Edgar Link pending
mrns-20230930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
mrns-20230930_def.xml Edgar Link unprocessable
mrns-20230930_lab.xml Edgar Link unprocessable
mrns-20230930_pre.xml Edgar Link unprocessable
mrns-20230930x10q_htm.xml Edgar Link completed
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending